Last reviewed · How we verify
Waldenström macroglobulinemia
Approved treatments
- Imbruvica · AbbVie
Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells. - Imbruvica · Rabin Medical Center
- Brukinsa · Beigene Usa Inc
Brukinsa blocks the BTK protein, which is involved in the activation of B cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Waldenström macroglobulinemia patent landscape — cliff calendar, originator estates, attackable patents
- Waldenström macroglobulinemia treatment landscape brief
- Waldenström macroglobulinemia treatment updates RSS
Frequently asked questions about Waldenström macroglobulinemia
What drugs treat Waldenström macroglobulinemia?
Tracked treatments include Imbruvica, Brukinsa.
What is the treatment for Waldenström macroglobulinemia?
Standard treatment for Waldenström macroglobulinemia includes Imbruvica, Brukinsa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Waldenström macroglobulinemia patent cliff · Waldenström macroglobulinemia CI report
- Treatment: Imbruvica · AbbVie
- Treatment: Imbruvica · Rabin Medical Center
- Treatment: Brukinsa · Beigene Usa Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing